Home LiteratureArticle Details
PMID: 18436115 Published · ppublish English Editorial Comment

Treating residual cardiovascular risk: will lipoprotein-associated phospholipase A2 inhibition live up to its promise?

Journal of the American College of Cardiology ·Vol. 51 ·No. 17 ·2008-04-29 ·Pages 1642-4

Koenig W

Abstract

暂无摘要

MeSH Terms
1-Alkyl-2-acetylglycerophosphocholine Esterase/antagonists & inhibitors,blood,drug effects Anti-Inflammatory Agents/therapeutic use Anticholesteremic Agents/therapeutic use Atorvastatin Coronary Artery Disease/drug therapy,enzymology Heptanoic Acids/therapeutic use Humans Inflammation/drug therapy Pyrroles/therapeutic use
Chemicals
Anti-Inflammatory Agents Anticholesteremic Agents Heptanoic Acids Pyrroles Atorvastatin 1-Alkyl-2-acetylglycerophosphocholine Esterase
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Koenig Wolfgang
Article Info
Journal
Journal of the American College of Cardiology
Abbr.
J Am Coll Cardiol
ISSN
1558-3597
DOI
10.1016/j.jacc.2008.02.025
Published
2008-04-29
Pages
1642-4
Language
English
Region
United States
NLM ID
8301365
Subset
IM
Corrections
CommentOn
PMID: 18436114
External Links
PubMed source DOI: 10.1016/j.jacc.2008.02.025 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2